Successful use of eculizumab to treat atypical hemolytic uremic syndrome in patients with inflammatory bowel disease

Successful use of eculizumab to treat atypical hemolytic uremic syndrome in patients with inflammatory bowel disease

Abstract Background Atypical hemolytic uremic syndrome is a rare group of disorders that have in common underlying complement amplifying conditions. These conditions can accelerate complement activation that results in a positive feedback cycle. The known triggers for complement activation can be di...

Full description

Bibliographic Details
Main Authors: Ramy M. Hanna, Noah Merin, Richard M. Burwick, Lama Abdelnour, Umut Selamet, Beshoy Yanny, Patrick Bui, Mary Fouad, Ira Kurtz
Format: Article
Language:English
Published: BMC 2019-09-01
Series:Thrombosis Journal
Subjects:
Atypical hemolytic uremic syndrome
Complement
Complement blockade
Thrombotic Microangiopathy
Inflammatory bowel disease
Crohn’s colitis/Crohn’s disease
Online Access:http://link.springer.com/article/10.1186/s12959-019-0207-7

Internet

http://link.springer.com/article/10.1186/s12959-019-0207-7

Similar Items